Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Research project to produce fish-free omega-3

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Biodegradable smart patch can detect and treat blood clots

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Content from other channels on our network

Tiny chip may cut AI's growing energy demands

Registrations now open for Clean Up Australia Day 2027

Tilt Renewables awarded five-star rating

"Solar tsunami" may hit businesses as installers go broke

Tiny molecule 'superhighways' to improve industrial processing

Accuris adds Australian legislation to Engineering Workbench

Leadership skills increasingly in demand for engineers

Novel method to reduce metal waste in manufacturing

ARENA backs hydrogen technology for steelmaking pilot

CSIRO suggests ways Australia can grow battery manufacturing sector

pladis program plans to help with a snacking reshape

Food safety testing hub opens in Melbourne

Contamination detection solutions for the food manufacturing industry

Six on the shelf: diverse new food products in November

tna's food packaging solution wins gold at the Good Design Awards 2026